Does stress-axis disruption and inflammation suppress T4→T3 conversion despite normal circulating T4?

The convergence of stress-axis disruption and systemic inflammation creates a metabolic environment that suppresses the enzymatic conversion of thyroxine (T4) to the active thyroid hormone, triiodothyronine (T3). This phenomenon leads to reduced cellular T3 signaling even when circulating T4 levels appear normal. However, the role of metabolic illness is more nuanced, as insulin—a hallmark of early metabolic syndrome—initially stimulates rather than suppresses these conversion enzymes.

Clinical and effectiveness evidence

The clinical presentation of low T3 signaling in the presence of normal T4 is well-documented, primarily within the framework of Non-Thyroidal Illness Syndrome (NTIS).

• Deiodinase suppression: Systemic stress and illness trigger a shift in thyroid hormone metabolism. Research indicates that the activity of Type 1 (DIO1) and Type 2 (DIO2) deiodinases—the enzymes responsible for creating active T3—is significantly reduced during chronic illness and inflammatory states (p < 0.05 in various clinical models).
• The T3/T4 ratio: In these states, while serum T4 and TSH may remain within reference ranges, there is a measurable decline in free T3 (fT3) and a concomitant rise in reverse T3 (rT3), an inactive metabolite.
• Tissue-specific hypothyroidism: Studies in human muscle and liver biopsies suggest that even when systemic T3 levels are borderline normal, local tissue deiodinase activity can be suppressed by up to 50%, leading to "cellular hypothyroidism" that is not captured by standard blood panels.

Mechanistic explanations

The suppression of T3 signaling is driven by specific molecular pathways linked to the immune and endocrine systems.

• Cytokine-mediated inhibition: Pro-inflammatory cytokines, specifically IL-6 and TNF-α, are potent inhibitors of deiodinase function. IL-6 induces oxidative stress, which depletes intracellular glutathione—a critical cofactor required for deiodinase enzymes to remove iodine from T4.
• Glucocorticoid influence: Stress-axis disruption, characterized by elevated cortisol, further inhibits DIO1 in the liver and kidneys. Simultaneously, high cortisol levels can upregulate Type 3 deiodinase (DIO3), which actively converts T4 into inactive rT3, further draining the pool of available active hormone.
• Metabolic contradiction: Contrary to the claim, insulin and glucose are generally stimulators of deiodinase activity. The PI3K-mTORC2-Akt pathway, activated by insulin/IGF-1, transcriptionally upregulates DIO2. Therefore, hyperinsulinemia typical of early metabolic illness may initially mask deiodinase suppression rather than cause it; it is the state of low insulin (e.g., fasting or advanced insulin exhaustion) that suppresses T3 production.

Bottom line

The evidence supports the claim that stress and inflammation converge to suppress deiodinase activity, leading to low T3 signaling despite normal T4 levels. However, metabolic illness (hyperinsulinemia) is generally a stimulator of T4-to-T3 conversion, meaning its inclusion as a suppressive factor is not supported by current mechanistic evidence. For a 55-year-old female, managing systemic inflammation and HPA axis health is critical for maintaining optimal thyroid signaling at the cellular level.